StockpollyBeta
Get App
Popularity #2,208
MNPR · NASDAQ · Biotechnology

Monopar Therapeutics (MNPR)

Develops ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology.

$96.63
After hours+0.15 (+0.16%)
At close$96.48(+0.79%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
2222211334657
Research & development1111110223435
11111122221,7382
General & administrative11111122221,7382
Other expenses0—00000000−1,7360
Operating income−2−2−2−2−2−11−3−3−4−6−5−7
000000111111
Interest income000000111111
Other non-operating income000000−1−10−1−1−1
Income before tax−2−2−2−2−1−11−3−2−3−5−4−5
Net income from continuing operations−2−2−2−2−1−11−3−2−3−5−4−5
Net income−2−2−2−2−1−11−3−2−3−5−4−5
EPS, basic−$0.14−$0.12−$0.10−$0.15−$0.11−$0.95−$0.38−$0.35−$0.48−$0.78−$0.46−$0.62
EPS, diluted−$0.14−$0.12−$0.10−$0.15−$0.11−$0.95−$0.38−$0.35−$0.48−$0.78−$0.46−$0.62
Weighted average shares, basic141516111111777799
Weighted average shares, diluted141516111111777799
EBITDA−20−2−2−1−11−3−2−4−5−4−5
Depreciation & amortization020000000000
EBIT−2−2−2−2−1−11−3−2−4−5−4−5